pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,381 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1173Endpoints890BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7582Rare Disease1868Cardiology1741Immunology1478Hematology1319Vaccines1197Pulmonology
  • OncLive launches weekly quiz on recent FDA oncology approvals
    OncLive released a weekly news quiz dated May 15, 2026, inviting readers to test their knowledge of recent oncology developments. The quiz focuses on three new FDA approvals in the oncology space…
    onclive · 3mo agoNeutral↗ source
  • Remembering Craig Venter: The Complex Legacy Behind the Human Genome Race
    Former NIH archivist Zachary Utz reflects on the recent death of Craig Venter, a prominent figure in genomics known for challenging conventional scientific approaches. Venter’s private company Cel…
    STAT · 3mo agoNeutral↗ source
← prev
page 78 of 96
next →
fda recalls69
fda medwatch60
fda press38
1171
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism473
Infectious Disease444
Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancer
A recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
onclive · 3mo agoPositive readoutPositive↗ source
  • BeOne secures FDA approval for lymphoma therapy
    BeOne received FDA approval for its lymphoma therapy, a notable achievement in a crowded therapeutic area. The agency’s review concluded that the treatment meets safety and efficacy standards, pla…
    STAT · 3mo agoApprovalPositive↗ source
  • Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for Duchenne
    Regenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…
    BioPharma Dive · 3mo agoRegulatoryPositive↗ source
  • Regenxbio reports successful Duchenne gene therapy trial, clearing path to FDA filing
    Regenxbio announced that its experimental gene therapy for Duchenne muscular dystrophy met its primary endpoints in a recent clinical trial, producing sufficient levels of a truncated muscle protei…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Supreme Court blocks restrictions, keeps mifepristone available through pharmacies and mail
    Supreme Court on Thursday issued an order that maintains women's ability to obtain the abortion medication mifepristone without requiring an in-person doctor visit. The decision overturns a lower-…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypes
    Ibrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Create Medicines secures $122M Series B to advance in vivo CAR-T therapies
    Create Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanoma
    A Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 data
    Biogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian Cancer
    AVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.…
    onclive · 3mo agoPositive readoutPositive↗ source
  • FDA commissioner Marty Makary exits, acting head Kyle Diamantas named as podcast discusses impact and Senate health race
    The Readout Loud podcast episode focused on health politics, featuring a discussion of FDA commissioner Marty Makary's departure. Hosts examined why Makary is leaving, which of his policies might…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Rintatolimod added to pembrolizumab and cisplatin yields 50% response rate in recurrent ovarian cancer
    A clinical study evaluated the combination of rintatolimod, pembrolizumab and cisplatin in patients with recurrent ovarian cancer. The regimen produced an objective response rate of 50%, indicatin…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Stage IV Breast Cancer Cases Rise Over Past Decade, Dana-Farber Study Shows
    A recent analysis by Dana-Farber Cancer Institute examined breast cancer diagnoses over the past ten years. The researchers found that the number of patients diagnosed with stage IV disease has ri…
    onclive · 3mo agoNeutral↗ source
  • Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapy
    Biogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…
    STAT · 3mo agoNegative readoutNeutral↗ source
  • Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026
    Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference. Central among the buz…
    onclive · 3mo agoNeutral↗ source
  • Triplet immunotherapy improves survival in HER2‑positive gastric cancer, suggesting broader immune activation
    New data from a study of HER2‑positive gastric cancer patients evaluated a triplet immunotherapy regimen. The analysis compared the combination against standard approaches and focused on overall su…
    onclive · 3mo agoPositive readoutPositive↗ source
  • Zenidatamab regimens show survival benefit in HER2-positive gastric cancer, but PD-L1 test variability raises treatment questions
    The HERIZON‑GEA‑01 study reports that zenidatamab‑based treatment schedules lead to a notable improvement in overall survival for patients with HER2‑positive gastric cancer. These efficacy finding…
    onclive · 3mo agoPositive readoutPositive↗ source
  • CREATE Medicines raises $122 million to advance CAR-T candidates into human trials
    CREATE Medicines, formerly Myeloid Therapeutics, announced a $122 million financing round. The funding came from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and other invest…
    STAT · 3mo agoDealPositive↗ source
  • Acting FDA Commissioner Kyle Diamantas Seen as Drama-Free Stabilizer for Biotech
    Kyle Diamantas has been named the acting commissioner of the Food and Drug Administration, stepping into the role after Marty Makary’s resignation. He previously led the FDA’s food safety division,…
    STAT · 3mo agoRegulatoryPositive↗ source
  • Dr. Jones reports GLP-1 agonists may outperform aspirin in colorectal cancer prevention and tolerability
    Dr. Colton Jones presented findings from a retrospective analysis that compared GLP-1 receptor agonists with aspirin for primary prevention of colorectal cancer. The analysis indicated that patien…
    onclive · 3mo agoPositive readoutPositive↗ source
  • FDA searches for new commissioner as Marty Makary departs, Trump administration outlines priorities
    Marty Makary is leaving his role at the FDA, as reported in STAT’s D.C. Diagnosis newsletter. The Trump administration has released a lengthy wish list for the next FDA commissioner, indicating th…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • STAT launches investigative series on alcohol epidemic killing 178,000 Americans annually
    STAT has begun a new investigative series that examines the United States’ ongoing alcohol crisis, which the outlet says results in roughly 178,000 deaths each year. The reporting team traveled na…
    STAT · 3mo agoNegative↗ source
  • STAT+: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing
    The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas, as the agency seeks to phase out…
    STAT · 3mo agoRegulatoryNeutral↗ source